News

Opportunities in the China Oncology Pharmaceutical Market

There are several trends emerging to create an ideal oncology market for biopharma companies in China. Below, we’ve highlighted some of the key attributes of the market. The Overall China Oncology Landscape China has the largest number of cancer patients globally: 4...

read more

China Real World Data Challenges…and Solutions

Real world data collection is difficult. In China, there are additional challenges to overcome. The main obstacles to real world data collection in China revolve around data privacy and data integration and quality. This article highlights below these obstacles, as...

read more

Highlights from ISPOR (Real World China)

GenomiCare’s sponsored ISPOR Webinar featured a cast of experts from Novartis, Roche, and AstraZeneca in a engaging  discussion about Real World Evidence in China. Key takeaways included: On the data, itself: Representativeness and Quality of data is paramount Overall...

read more
GenomiCare Is on List of 2020 Deloitte China Technology Fast 50 & China Rising Star

GenomiCare Is on List of 2020 Deloitte China Technology Fast 50 & China Rising Star

The 2020 China Technology Fast 50 & China Rising Star lists were officially published by the Beijing office of Deloitte on December 9 and reported by dozens of news outlets. GenomiCare is on list of the 2020 China Rising Star thanks to its “two-wheel-drive” business model, powerful translational cancer research, and flexible data solutions for clinical oncology drug development.

read more